Pfizer’s three largest patent-exposed drugs brought in about $4 billion in the second quarter alone. Within roughly 18 months, generic versions of all three are due to reach the US market.
The Pfizer stock price traded near $29.91 on October 29, up about 21% this year. In other words, investors are paying more for a company whose biggest products are about to lose protection.
That paradox frames the third-quarter report on Tuesday, November 3. This analysis weighs the patent cliff against the pipeline built to replace it. It also examines what the 5.8% dividend yield really depends on.
Where the Pfizer Stock Price Stands Before November 3
Pfizer shares bottomed out in 2025, and the climb back since then has been slow, though consistent. These days the price holds above its 50-day moving average, and above the 200-day one too.
🔗6 Simple RSI Trading Strategies You Can Use Today
PFE Stock Price Markers
| Intel Stock Price Marker / Technical Metric | Figure / Market Value |
|---|---|
| Share Price (October 29, 2026 Intraday) | About $29.91 per share |
| Closing Share Price (October 23, 2026) | $30.03 per share |
| 50-Day / 200-Day Moving Averages | $28.46 (50-Day) / $26.74 (200-Day) |
| Total Market Capitalization | About $170.0 Billion |
| Consensus Price Target (MarketBeat) | About $28.72 per share |
| Annual Dividend Rate & Yield | $1.72 per share / About 5.8% dividend yield |
The Price Has Passed the Analyst Target
The fact is that the share now sits higher than the price that analysts, on average, are targeting. MarketBeat lists 5 Buy calls, 14 Hold, and 2 Sell. As for TIKR, its data shows the forward P/E going from roughly 9x at 2025’s close to roughly 11x. Today, it’s nearer to 11x.
🔗Analyst Price Targets Explained
A Higher Multiple on Falling Estimates
However, the multiple expanded while estimates fell. TIKR shows next-twelve-month EPS estimates dropping from $2.96 at the end of 2025 to $2.76. Part of that decline reflects the forecast window reaching into 2027, when patent losses begin.
Put differently, the investor is valuing each dollar of future earnings forecast lower at a higher price. In effect, the rally has raced ahead of Wall Street expectations, raising expectations for Tuesday.
Trader Takeaway: The PFE stock price already reflects improved sentiment. Further gains likely need upgrades to estimates, not just a clean quarter.
For traders, the 50-day average near $28.46 is therefore the first reference level if the report disappoints.
The Patent Cliff in Numbers
Three products carry most of Pfizer’s near-term exposure. Each faces US generic competition between 2027 and 2028.
Pfizer Inc. (PFE) Key Pharmaceutical Portfolio
| Product Name | Primary Therapeutic Indication | Q2 2026 Revenue Contribution | U.S. Exclusivity Outlook & Patent Expiration Schedule |
|---|---|---|---|
| Eliquis (Apixaban) (Co-promoted with BMS) | Oral Anticoagulant / Blood Thinner | $2.43 Billion | Settled generic entry scheduled for April 1, 2028 (post composition patent expiration) |
| Ibrance (Palbociclib) | HR+/HER2- Metastatic Breast Cancer | $1.06 Billion | Key U.S. composition and secondary patents expiring through 2027 |
| Xtandi (Enzalutamide) (Partnered with Astellas) | Prostate Cancer (Castration-Resistant) | $0.53 Billion | Key U.S. patent protection expiring in 2027 |
| Combined Portfolio Total | Core Oncology & Cardiovascular Blockbusters | $4.02 Billion | Approaching major 2027–2028 U.S. loss-of-exclusivity cliff |
Annualizing that combined figure gives about $16 billion of revenue, by our calculation. That equals roughly a quarter of 2026 guidance. Generic entry typically erodes a small-molecule drug’s US sales sharply within the first year.
🔗12 Trade Management Golden Tips For Day Traders
Price Controls Arrive First
Pricing pressure starts even earlier. Medicare selected Eliquis among the first drugs for price negotiation under the Inflation Reduction Act.
The negotiated price took effect in 2026. Meanwhile, Pfizer already guided to about $1.5 billion of revenue loss from generics and biosimilars this year.
🔗Patent Cliffs in Pharma Stocks Explained
How the Cliff Hits Revenue
What does losing exclusivity look like in practice? Well, generic makers come in, and the price drops hard. That hole in revenue is the one Pfizer’s new launches have to fill.
The cliff is not a single event. It is a two-year slope that starts with price controls before patents expire.
Trader Takeaway: Roughly a quarter of Pfizer’s revenue faces generic exposure by 2028. The pipeline must replace it before the dividend can grow again.
Therefore, Eliquis pricing or generic timing comments on Tuesday’s call can move the shares more than revenue.
🔗Walmart Stock (WMT): Is It the Next Global Tech Monopoly?
2026 So Far: Growth Underneath, Charges on Top
Pfizer’s 2025 results showed the post-pandemic reset nearly complete. COVID products fell further in 2026, but the rest of the business kept growing.
Pfizer Inc. (PFE) Financial Performance Overview
| Financial Metric & Performance Indicator | Full-Year FY2025 Results | Fiscal Q2 2026 Results |
|---|---|---|
| Total Net Revenue & Year-over-Year Trend | $62.6 Billion (-2.0% YoY reported) | $15.0 Billion (+3.0% YoY reported) |
| Core Growth Excluding Comirnaty & Paxlovid | +6.0% operational growth | +5.0% operational growth |
| Launched and Acquired Products Contribution | Not applicable / baseline period | +18.0% operational growth |
| Adjusted Diluted Earnings Per Share (EPS) | $3.22 per share | $0.77 per share |
| Reported Diluted EPS / (Loss Per Share) | $1.36 per share | -$0.04 per share (impacted by non-cash impairments) |
🔗How to Read an Earnings Report
Impairments Behind the EPS Gap
Why is reported EPS so far below the adjusted figure? The answer lies in write-downs: Pfizer booked $4.3 billion of non-cash impairments in the second quarter. The largest, $3.8 billion, related to sigvotatug vedotin. That experimental lung cancer drug failed its Phase 3 trial.
🔗Earnings Per Share (EPS) Explained
Guidance Still Moved Higher
Even so, Pfizer lifted its revenue guidance for 2026, which now ranges from $60.5 billion to $62.5 billion. Non-COVID products should add about $1.5 billion more than planned. That offsets a COVID forecast cut to about $4 billion. As for adjusted EPS, the company left its guidance unchanged at $2.80 to $3.00.
Trader Takeaway: Underlying growth is real but modest. Impairments show that acquired pipeline assets carry write-down risk. As a result, a new impairment is the line most likely to put pressure on the stock after Tuesday’s report.
Beyond the Cliff: What Still Grows
Not every major product faces near-term generics. Several franchises grew in the second quarter, and they form the base Pfizer must build on.
Pfizer Inc. (PFE) Key Product Portfolio & Franchise Performance
| Product Name & Therapeutic Franchise (Q2 2026) | Q2 2026 Revenue | Operational Growth (YoY) | Primary Disease Category / Indication |
|---|---|---|---|
| Vyndaqel Family (Tafamidis) | $1.76 Billion | +8.0% Operational Growth | Transthyretin Amyloid Cardiomyopathy (Rare Heart Disease) |
| Padcev (Enfortumab vedotin) | $667 Million | +23.0% Operational Growth | Advanced Urothelial / Bladder Cancer |
| Nurtec ODT / Vydura (Rimegepant) | $421 Million | +17.0% Operational Growth | Acute & Preventive Migraine Therapy (CGRP Inhibitor) |
| Abrysvo (RSV Vaccine) | $208 Million | +43.0% Operational Growth | Respiratory Syncytial Virus (RSV) Preventive Vaccine |
| Prevnar Family (Pneumococcal Vaccines) | $1.34 Billion | -4.0% Operational Growth | Pneumococcal Conjugate Vaccine Protection |
| Comirnaty (COVID-19 Vaccine) | $261 Million | -34.0% Operational Growth | COVID-19 mRNA Vaccine Immunization |
| Paxlovid (COVID-19 Antiviral) | $21 Million | -95.0% Operational Growth | COVID-19 Oral Antiviral Treatment |
Specialty Products Up, COVID Products Down
The pattern is clear. Specialty and oncology products grow, while COVID products have almost vanished. Paxlovid sales fell to just $21 million in the quarter.
Prevnar Feels the Competition
On the other hand, Prevnar, which is Pfizer’s largest vaccine portfolio, saw a decline of 4% amid growing competition in pneumococcal vaccines. The revenue engine is there, but it is still smaller than the revenue that is about to go away.
Trader Takeaway: Vyndaqel, Padcev and Nurtec carry the near-term growth story. Their combined quarterly sales still trail the three products facing generics.
Oncology: Seagen Delivers Hits and Misses
Pfizer paid about $43 billion for Seagen in 2023 to anchor its post-COVID oncology business. So far, the results look mixed.
Padcev, Tukysa and a Phase 3 Miss
Padcev, a bladder cancer drug, recorded a 23% increase in Q2. In October, Tukysa received FDA approval as a first-line maintenance therapy for HER2-positive metastatic breast cancer. However, sigvotatug vedotin, the first new Seagen drug to reach Phase 3, missed its survival goal in June.
Elrexfio Wins MagnetisMM-32
Pfizer’s own bispecific antibody, Elrexfio, offered a bright spot. On October 27, Pfizer reported Phase 3 results for Elrexfio in relapsed multiple myeloma. The drug beat three standard regimens in the MagnetisMM-32 trial.
At an interim analysis, the estimated 18-month progression-free survival rate reached 68%. The trial has not yet reached median progression-free survival. Pfizer plans to file the data with regulators.
🔗Biotech and FDA Catalyst Trading
Pfizer Inc. (PFE) Oncology Portfolio Pipeline Developments & Regulatory Signals
| Oncology Asset | Latest Clinical / Commercial Development | Strategic Signal & Portfolio Impact |
|---|---|---|
| Padcev (Enfortumab vedotin) | Robust commercial performance with Q2 sales reaching $667 million (+23% operational growth YoY) | Growing core asset driving robust genitourinary franchise expansion |
| Tukysa (Tucatinib) | FDA front-line maintenance approval secured in October for HER2+ metastatic breast cancer | Label expansion into earlier-line maintenance treatment settings |
| Elrexfio (Elranatamab) | Phase 3 MagnetisMM-32 study successfully met primary endpoint on October 27 | Earlier-line opportunity validated in relapsed/refractory multiple myeloma |
| Sigvotatug Vedotin | Phase 3 non-small cell lung cancer trial miss reported in June, resulting in a $3.8B impairment | Clinical setback leading to major non-cash intangible asset write-down |
Oncology now carries Pfizer’s growth case, but one failed trial erased billions in book value overnight.
Trader Takeaway: Elrexfio and Tukysa add new revenue paths. The Seagen write-downs show why investors discount pipeline value until approvals arrive. In the same manner, the Elrexfio filing timeline may get more attention on the call than oncology sales.
Obesity: The Metsera Bet After the Cuts
Pfizer concluded the acquisition of Metsera in November 2025 amid a bidding war with Novo Nordisk for $65.60 in cash per share, an enterprise value of around $7.0 billion. Metsera holders also received contingent rights worth up to $2.3 billion more.
🔗How Mergers and Acquisitions Move Stocks
A Monthly GLP-1 Heads Into Phase 3
The lead asset, PF-08653944 (formerly MET-097i), is an injectable GLP-1 drug for monthly dosing. Pfizer reported Phase 2b results in February.
Placebo-adjusted weight loss reached up to 12.3% at 28 weeks. Pfizer expects about ten Phase 3 trials to advance in 2026.
Two Programs Dropped in August
However, the pipeline also shrank. In August, Pfizer dropped MET-224o, an oral drug from Metsera, and a GIPR antagonist after Phase 2a data. Pfizer now has one remaining oral GLP-1 candidate.
Monthly dosing is Pfizer’s chosen point of difference in a market Novo Nordisk and Eli Lilly dominate.
🔗Magnificent 7 Stocks: Where Investors Are Finding Growth in 2026
Trader Takeaway: Obesity offers the largest upside in the pipeline. Phase 3 results, not Phase 2 headlines, will decide its value. For traders, these readouts are therefore long-dated catalysts rather than earnings-week ones.
Buying Innovation From China
Pfizer increasingly sources early-stage assets from Chinese biotechs. In May, it signed a deal with Innovent Biologics covering 12 early oncology programs.
The transaction has a value of $650 million upfront and can reach a value of up to $10.5 billion. The upfront amount will be accounted for in Q3 as part of expenses worth approximately $0.10 per share.
Cheaper Breadth, Higher Policy Risk
Such an approach delivers cheaper pipeline breadth but at the same time links future development with partners from a country that increasingly becomes subject to US policymaker scrutiny.
Pfizer has used the model before. Its 2025 business development spending of about $8.8 billion covered Metsera and an in-licensing deal with China’s 3SBio.
🔗Alphabet Stock Price Before Q3 Earnings: DeepMind’s Biology Bet vs. the Cloud Bi
A Payoff Beyond the Cliff
Early-stage licensing carries a long payoff horizon. Most of the 12 Innovent programs will not reach late-stage trials before the patent cliff passes. They address Pfizer’s 2030s growth, not the 2027 to 2028 gap.
Trader Takeaway: China licensing adds cheap pipeline breadth. It does little for the next three years of revenue. The Innovent charge, however, will weigh on reported third-quarter EPS, so the market already expects a lower headline figure.
The Dividend Math
The dividend is the main reason many investors own Pfizer. Its safety depends on cash flow, debt, and cost cuts.
🔗Dividend Stocks Explained
Adjusted vs Reported Payout
That ratio looks manageable on adjusted earnings. On reported earnings, which include impairments, MarketBeat shows a payout above 200%.
Pfizer Inc. (PFE) Capital Allocation & Balance Sheet Structure
| Balance Sheet Metric / Capital Allocation Item | Financial Figure & Corporate Parameter |
|---|---|
| Common Dividends Paid (Full-Year 2025) | $9.8 Billion returned to shareholders |
| Common Dividends Paid (First Half 2026) | $4.9 Billion disbursed |
| Total Debt Obligations (As of June 28, 2026) | About $63.2 Billion (Total long-term and short-term debt load) |
| Cash & Short-Term Liquid Investments | About $11.7 Billion |
| Common Share Repurchases (2025–2026 Period) | None (Capital prioritized for debt service and dividends) |
| Combined Cost-Savings Targets Through 2029 | About $9.7 Billion in cumulative operational efficiencies |
Cost Cuts Carry the Cover
That savings figure is the sum of two programs. The cost-base program targets about $6.7 billion, and manufacturing optimization about $3.0 billion.
Earnings cover the dividend today, but that depends on cost cuts landing before the patent cliff fully bites.
Trader Takeaway: With no buybacks and $63 billion of debt, the dividend competes with deleveraging for cash. Growth in the dividend looks unlikely before 2029. Since many holders own the stock for income, dividend language on the call may outweigh EPS.
Activists and Insiders
Starboard Value took a roughly $1 billion stake in late 2024 and criticized Pfizer’s capital allocation. It sold its remaining shares during the third quarter of 2025.
Bourla’s $1 Million Purchase
Albert Bourla, who is Pfizer’s CEO, purchased 38,000 shares in his name on August 12, 2026. The price per stock at which he bought was $26.34, making the purchase amount to about $1 million.
The stock has appreciated by about 14% since then. It’s not common for a chief executive to buy shares on the open market. For that reason, investors tend to see such a move as a sign of confidence.
🔗Insider Trading and Form 4 Filings Explained
Timing of the Buy
The purchase came weeks after the significant impairment and before the October Elrexfio data. With Starboard gone, the main pressure on management now comes from the stock price itself.
Trader Takeaway: Activist pressure has faded, and the CEO has bought stock. Execution on Phase 3 trials will now drive the governance narrative.
What Options Imply for November 3
TIKR cites consensus third-quarter revenue near $15.9 billion and adjusted EPS near $0.73. The Innovent charge accounts for most of the expected decline from $0.87 a year earlier.
Expected Move and Position Size
Let’s say the implied move is 4% (a hypothetical number). Then $29.91 × 0.04 gives about $1.20, which puts the range at roughly $28.70 to $31.10. Live options data will differ.
Position size can follow the same logic. A trader with $100,000 in the account who risks 1% is putting $1,000 on the table.
Now, suppose the trader places the stop one expected move away from the entry. That means $1,000 ÷ $1.20, which comes to about 833 shares. We show these numbers as an example only, not as a trade plan.
🔗Position Sizing in Forex & Stocks
Q3 Earnings Scenarios for PFE
| Market Scenario | Forward Guidance & Fundamental Signal | Likely Effect on Stock Price Action & Technical Levels |
|---|---|---|
| Constructive Scenario | Newly launched and acquired commercial products accelerating toward 20.0% growth; full-year financial guidance raised by executive management | Bullish momentum maintaining firm support to hold equity valuations above the $30.00 threshold |
| Base Case Scenario | Quarterly financial results tracking near consensus estimates; corporate forward guidance strictly reaffirmed | Range-bound technical consolidation within established trading bands |
| Pressured Scenario | Unanticipated pipeline impairment charges or downward revisions to forward revenue guidance | Post-earnings profit-taking pullback triggering a possible slide back toward the 50-day moving average |
The thresholds above are an editorial call rather than guidance from the company. Growth in launched products matters more than the headline EPS.
The Risks That Matter for the Pfizer Stock Price
Each of the risks below can show up in Tuesday’s numbers, in the guidance, or on the call itself.
- Patent cliff. Eliquis, Ibrance, and Xtandi face generics in 2027 and 2028.
- Price controls. Medicare negotiation already cuts Eliquis pricing.
- Pipeline failures. Sigvotatug vedotin’s miss cost $3.8 billion in impairments.
- Obesity competition. Novo Nordisk and Eli Lilly lead with approved drugs.
- Leverage. Debt stands near $63 billion with no buybacks.
- Valuation. The stock trades above the consensus target.
🔗Risk Management in Stocks: A Complete Guide 2026
Closing Thoughts
Pfizer has rebuilt its growth engine faster than many expected. Launched and acquired products grew 18% in the second quarter. Elrexfio won a key trial, and the obesity program advanced to Phase 3. The stock responded with a 21% gain this year.
However, the patent cliff remains the larger force. About $16 billion of annualized revenue faces generic entry by 2028, and price controls arrive first. The Pfizer stock price now assumes the pipeline will fill that gap on time.
In our view, the dividend looks secure through the cliff, supported by cost cuts. What happens to growth after 2028 is a different question, though. The answer depends on Phase 3 trials whose results are still pending.
NFA. DYOR. The content of this article is for informational purposes only, and it should not be taken as investment advice.
If you liked this post make sure to share it!
